Gene Synthesis Market Size, Share & Trends Analysis Report By Service (Antibody, Viral), By Application (Gene & Cell Therapy Development, Disease Diagnosis), By End Use, By Method, By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global gene synthesis market size was valued at USD 1.47 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 18.1% from 2021 to 2028. The supportive government policies associated with synthetic biology are key driving factors of the market. With the growing demand for synthetic biology, investors have shifted their focus on this field over the past few years. In 2020, approximately, USD 8 billion were invested in the synthetic biology field by public and private financing. The ongoing COVID-19 pandemic has been advantageous for the market, in terms of new growth opportunities. Scientific communities are exploring untapped avenues in the space, thereby contributing to revenue growth. For instance, researchers at the National Institute of Standards and Technology (NIST) have produced synthetic gene fragments from the COVID-19 virus to help diagnostic developers develop more reliable and accurate diagnostic tests for the disease.

Advances in synthetic DNA technology are gaining traction as a viable measure to address concerns related to the growing number of emerging pathogens and the threats of the next global pandemic. This promising strategy to readily propagate and help characterize genes of interest can promptly progress to respond to the current SARS-CoV-2 pandemic as well as near-future pandemics involving other novel pathogens.

In the past few years, targeted therapy is gaining increasing attention by researchers as well as by biotechnology & pharmaceutical companies. It has emerged as an important way of disease management. Targeted therapy in combination with chemotherapy and immunotherapy is expected to witness significant growth in the near future, in turn, creating lucrative opportunities for the emerging, as well as key players, in the market.

A shortage of skilled professionals in the field of biotechnology and gene synthesis is a major hurdle for the market growth, as the market players require experienced and trained staff at their facilities. Thus, companies are now collaborating with various universities and offering on-site training, online workshops, and sponsored projects to develop the right professionals, thereby driving the market growth.

Method Insights

The solid-phase synthesis segment captured the maximum revenue share of more than 36% in 2020 owing to the highest adoption rate over the past few years. Also, the high accuracy of this method further boosts its deployment among the therapy developers and research settings. However, its high cost and low output hamper its usage in some cases, creating opportunities for other methods. PCR- and chip-based methods are anticipated to register significant CAGRs over the forecast period. These methods allow the synthesis of larger fragments at a lower rate, resulting in their increased usage.

Furthermore, using cell systems, the PCR-based method offers accuracy of the gene sequence. With the relative ease of artificial gene synthesis facilitated by various methods, prospective scientific innovators are now significantly speeding up the rapid preparation of DNA fragments required for the R&D of synthetic nucleic acid-based therapeutics. This is anticipated to bolster the adoption across all three methods based on research needs.

Service Insights

The antibody DNA synthesis segment led the market with a revenue share of more than 60% in 2020. The presence of a substantial number of market players offering services for antibody DNA synthesis has resulted in the dominance of this segment. Companies are offering services to pharma/biotech companies and research institutions to allow cloning and synthesis of antibody heavy/light chain sequences into any custom vector. On the other hand, the viral gene synthesis segment is estimated to register the fastest CAGR from 2021 to 2028 owing to the increasing virus vector-related R&D activities.

Moreover, companies are engaged in the synthesis of all non-structural and structural protein genes or gene fragments of the SARS-CoV-2. This has accelerated the acquisition of the virus recombinant proteins and has encouraged the research of protein structural biology of the virus particles. The virus-related target gene synthesis has been mass-produced and is designed for research use only. These factors are expected to contribute to the growth of this segment.

Application Insights

The gene & cell therapy development segment accounted for the largest revenue share of more than 35% in 2020. This is anticipated to continue expanding the pipeline of advanced therapies for treating chronic conditions. These therapies are gaining immense popularity among therapy developers owing to their advanced efficiency in treating conditions that are not treatable using the conventional mode of disease treatment. Academic institutions and companies across the globe are actively engaged in the development of new therapies, which are likely to boost the demand for services in this market.

In addition, the companies are also focusing on investments and funding to extend their capabilities for stem cell therapies and regenerative medicines. On the other hand, the vaccine development segment is anticipated to witness the fastest CAGR from 2021 to 2028 due to the rising concerns regarding future pandemics. A substantial number of companies are investing heavily in vaccine development post-onset of the COVID-19 pandemic. This is expected to show a positive impact on the market, in terms of growth opportunities for the vaccine development-based gene synthesis market.

End-use Insights

The academic and government research institutes segment dominated the global market in 2020 accounting for a revenue share of over 54%. The segment is estimated to expand further at the fastest CAGR from 2021 to 2028 owing to the high usage of gene synthesis services in research settings. The research institutes are collaborating with service providers to accelerate their research programs that demand the synthesis and characterization of gene fragments.

The biotechnology & pharmaceutical companies segment is anticipated to witness notable growth during the forecast period. Increasing usage of synthesis biology by biotech companies for the development of novel disease management modalities is expected to bolster the segment growth.

Regional Insights

North America accounted for the largest revenue share of more than 38% in 2020 due to the presence of major players and supportive government initiatives pertaining to the training and implementation of synthetic biology programs. The rising implementation of gene editing and synthesis-related procedures by drug and diagnostic developers in the U.S. facilitates regional market growth. In addition, regulatory authorization, and commercialization of synthetic gene products in the region have supplemented the market growth.

Also, the recent approval of a high number of cellular and gene therapies in the region further drives the investment by other companies in this space. Asia Pacific is estimated to register the fastest CAGR from 2021 to 2028. This can be attributed to the rising investments by global companies in the regional market. Moreover, the presence of some key companies in emerging nations, such as China and India, contributes to the market growth.

Key Companies & Market Share Insights

The market is anticipated to witness rising competition in the coming years. The rising number of new market entrants further substantiates the intensifying competition among the key stakeholders. These players are engaged in strategizing to capitalize the untapped avenues and enhance their presence in the space by virtue of a broad service portfolio. Some of the prominent players in the global gene synthesis market include:

• GenScript

• Brooks Automation, Inc. (GENEWIZ)

• Boster Biological Technology

• Twist Bioscience

• ProteoGenix

• Biomatik

• ProMab Biotechnologies, Inc.

• Thermo Fisher Scientific, Inc.

• Integrated DNA Technologies, Inc.

• OriGene Technologies, Inc. 

 Gene Synthesis Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global gene synthesis market report on the basis of method, service, application, end use, and region:

• Method Outlook (Revenue, USD Million, 2017 - 2028)

  • Solid-phase Synthesis

  • Chip-based Synthesis

  • PCR-based Enzyme Synthesis

• Service Outlook (Revenue, USD Million, 2017 - 2028)

  • Antibody DNA Synthesis

  • Viral DNA Synthesis

  • Others

• Application Outlook (Revenue, USD Million, 2017 - 2028)

  • Gene & Cell Therapy Development

  • Vaccine Development

  • Disease Diagnosis

  • Others

• End-use Outlook (Revenue, USD Million, 2017 - 2028)

  • Biotechnology & Pharmaceutical Companies

  • Academic & Government Research Institutes

  • Contract Research Organizations

• Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • France

    • U.K.

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • South Korea

    • India

  • Latin America

    • Brazil

    • Mexico

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia